Featured Research

from universities, journals, and other organizations

Nonhormonal Treatment Regimens Improve Survival In Patients With Metastatic Breast Cancer

Date:
December 23, 2008
Source:
Journal of the National Cancer Institute
Summary:
Nonhormonal treatment regimens, including anthracycline-based regimens and taxanes, have improved overall survival in women with advanced (metastatic or recurrent inoperable) breast cancer over the last 35 years, according to a systematic review in the Journal of the National Cancer Institute.

Nonhormonal treatment regimens, including anthracycline-based regimens and taxanes, have improved overall survival in women with advanced (metastatic or recurrent inoperable) breast cancer over the last 35 years, according to a systematic review published December 9 in the Journal of the National Cancer Institute.

Related Articles


Numerous regimens have been tested in advanced breast cancer. However, each of the trials has compared only a few regimens, making it difficult for researchers and clinicians to know the relative merit of the individual regimens.

To learn how regimens compare with one another, John P. A. Ioannidis, M.D., of the University of Ioannina School of Medicine in Greece and colleagues performed a meta-analysis of 128 clinical trials that included 148 comparisons between regimens and that enrolled 26,031 women with advanced breast cancer. The investigators used single-agent chemotherapy with old non-anthracycline drugs as the baseline for comparison within their meta-analysis.

The use of anthracycline regimens led to a 22%–33% relative risk reduction in overall mortality as compared with older single agent chemotherapy. Single drug taxane treatment led to a similar relative risk reduction of 33 percent, while the combination of a taxane with capecitabine or gemcitabine led to a 51 percent relative risk reduction over the single agent chemotherapy. Most of the regimens appeared to have similar efficacy when used in women who had not been previously treated and in women who had had prior therapy.

"Our meta-analysis quantifies the progress achieved in the treatment of advanced breast cancer with nonhormonal systemic treatment in the last 35 years. Several regimens have shown effectiveness, and for some of them, the treatment effects are practically indistinguishable in magnitude," the authors write. "Given that subsequent lines of treatment can confer similar relative benefits as the first-line setting, one can exploit the survival benefits conferred by several effective regimens used in sequential fashion."

In an accompanying editorial, Philippe Bedard, M.D., and Martine Piccart-Gebhart, M.D., Ph.D., of the Jules Bordet Institute in Brussels, Belgium, note that there has been no consensus regarding the best dosage, timing, sequence or combination of therapies for the treatment of metastatic breast cancer because standard comparators have not been available. Therefore, the work of Ioannidis and colleagues is important.

Given the investigators' finding that many of the regimens have similar relative effectiveness in previously-untreated and -treated patients, no clear order of use appears from the meta-analysis. Other considerations, such as toxicity, will continue to help drive the choice of regimen for individual therapy, the editorialists argue.

"Although this network meta-analysis is unlikely to alter routine clinical practice, it provides a solid evidence-based foundation to support the observation that the survival of women diagnosed with advanced breast cancer has improved because of more active systemic chemotherapy and targeted therapy," the editorialists write. "This should provide hope to patients, investigators, industrial sponsors, and regulatory agencies alike that well-designed clinical trials with novel systemic therapies can further alter the natural history of this devastating disease."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal References:

  1. Mauri D et al. Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer. J Natl Cancer Inst, 2008; 100:1780-1791 DOI: 10.1093/jnci/djn414
  2. Bedard PL and Piccart-Gebhart MJ. Nonhormonal Systemic Therapy for Advanced Breast Cancer: Do the Math!. J Natl Cancer Inst, 2008; 100: 1745-1747 DOI: 10.1093/jnci/djn433

Cite This Page:

Journal of the National Cancer Institute. "Nonhormonal Treatment Regimens Improve Survival In Patients With Metastatic Breast Cancer." ScienceDaily. ScienceDaily, 23 December 2008. <www.sciencedaily.com/releases/2008/12/081209221501.htm>.
Journal of the National Cancer Institute. (2008, December 23). Nonhormonal Treatment Regimens Improve Survival In Patients With Metastatic Breast Cancer. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2008/12/081209221501.htm
Journal of the National Cancer Institute. "Nonhormonal Treatment Regimens Improve Survival In Patients With Metastatic Breast Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/12/081209221501.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Earthworms Provide Cancer-Fighting Bacteria

Earthworms Provide Cancer-Fighting Bacteria

Reuters - Innovations Video Online (Dec. 21, 2014) Polish scientists isolate bacteria from earthworm intestines which they say may be used in antibiotics and cancer treatments. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Reuters - Innovations Video Online (Dec. 21, 2014) A team of scientists led by Danish chemist Jorn Christensen says they have isolated two chemical compounds within an existing antipsychotic medication that could be used to help a range of failing antibiotics work against killer bacterial infections, such as Tuberculosis. Jim Drury went to meet him. Video provided by Reuters
Powered by NewsLook.com
Hugging It Out Could Help You Ward Off A Cold

Hugging It Out Could Help You Ward Off A Cold

Newsy (Dec. 21, 2014) Carnegie Mellon researchers found frequent hugs can help people avoid stress-related illnesses. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins